Georgia regulators greenlight home delivery for registered patients and permit university research with state-program products—changes that could reshape access and evidence-building.

An NCSL-backed milestone now has medical cannabis permitted in 40 states, three territories, and DC. Here’s what that shift means for patients and the DMV.

Marijuana Venture spotlights Chris Violas in its 40 Under 40. We examine how tech‑minded leadership can shape patient delivery services, science‑based safeguards, and DMV implications.

Most psychedelic use happens outside hospitals. Here’s why community-led, non-clinical models matter—and how DMV patients can navigate access, safety, and support today.

NORML reports a decade-long study in back pain patients linking medical cannabis therapy to sustained pain relief and sharply reduced reliance on pharmaceuticals.

A new driving-simulator study found no intoxication or cognitive impairment from 15–1,500 mg CBD. Here’s what that means for patients, drivers, and DMV consumers.

Disabled and autistic participants face distinct physiological and sensory needs during psychedelic work. Here’s how to make ceremonies safer—and what DMV readers should know.

Psychedelic Science Review reports a rapid rise in psilocybin interest, with 100+ clinical trials since the early 2000s and recent studies signaling strong therapeutic potential.